Xoma, a drug royalty specialist, buys another ‘zombie’ biotech
Written by
BioPharma Dive
Published
0
comments
0
min
A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying and shutting down struggling drugmakers.